Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
A Czira, V Banks, G Requena, R Wood, T Tritton, E Ha… - 2021 - Eur Respiratory Soc
Background: ICS/LABA therapy is recommended by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) as maintenance therapy for some patients with COPD …
Obstructive Lung Disease (GOLD) as maintenance therapy for some patients with COPD …
Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 …
C Li, W Cheng, J Guo, W Guan - International Journal of Chronic …, 2019 - Taylor & Francis
Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2–agonists
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
I Naya, L Tombs, DA Lipson, I Boucot, C Compton - Respiratory research, 2019 - Springer
Background Symptomatic patients with chronic obstructive pulmonary disease (COPD) and
low exacerbation risk still have disease instability, which can be improved with better …
low exacerbation risk still have disease instability, which can be improved with better …
Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy
LGS Bengtson, M DePietro… - Therapeutic …, 2018 - journals.sagepub.com
Background: Randomized clinical trials have shown long-acting mono bronchodilator
therapy to be efficacious in improving lung function and dyspnea, while reducing …
therapy to be efficacious in improving lung function and dyspnea, while reducing …
Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive …
JC Samp, MJ Joo, GT Schumock… - … : The Journal of …, 2017 - Wiley Online Library
Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis
RL DiSantostefano, H Li, DB Rubin, DA Stempel - BMJ open, 2013 - bmjopen.bmj.com
Objective To identify subsets of chronic obstructive pulmonary disease (COPD) patients who
are more protected from exacerbations with the use of an inhaled corticosteroid/long-acting …
are more protected from exacerbations with the use of an inhaled corticosteroid/long-acting …
[HTML][HTML] Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease
WM Brunner, N Siddiqui, MB Scribani… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Background Chronic obstructive pulmonary disease (COPD) is prevalent in rural areas of
the USA. Long-acting inhaled bronchodilators (LABDs) are a key tool in COPD management …
the USA. Long-acting inhaled bronchodilators (LABDs) are a key tool in COPD management …
Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
SE Petite - Annals of Pharmacotherapy, 2017 - journals.sagepub.com
Objective: To compare the available literature regarding the use of long-acting muscarinic
antagonist (LAMA)/long-acting β2 agonists (LABA) and inhaled corticosteroid (ICS)/LABA …
antagonist (LAMA)/long-acting β2 agonists (LABA) and inhaled corticosteroid (ICS)/LABA …
Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada
Background The patterns of medication use in chronic obstructive pulmonary disease
(COPD) may change over time due to the availability of new medications, updates in …
(COPD) may change over time due to the availability of new medications, updates in …
Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
P Kardos, S Worsley, D Singh… - … journal of chronic …, 2016 - Taylor & Francis
Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators
and their combination are recommended for the maintenance treatment of chronic …
and their combination are recommended for the maintenance treatment of chronic …